ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
41.22
1.40%
US Tech 100
21,007.20
0.84%
S&P 500
6,071.17
0.53%
US Dollar vs CAD
1.44365
-0.39%
Bitcoin
104,137.22
-0.57%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Mineralys Therapeutics Inc (MLYS) Share Price

Mineralys Therapeutics Inc

Mineralys Therapeutics Inc (MLYS)

NASDAQ
10.27
-0.09
(-0.87%)
Closed January 31 3:00PM
Delayed by 15 minutes
10.06
-0.21
(-2.04%)
After Hours: 6:59PM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
10.27
Bid
9.00
Ask
13.50
Volume
130,667
10.22 Day's Range 10.78
8.58 52 Week Range 16.905
Market Cap
511.124M
Previous Close
10.36
Open
10.47
Last Trade
500
@
10.06
(formt)
Last Trade Time
Financial Volume
US$ 1,367,592
VWAP
10.4662
Average Volume (3m)
230,622
Shares Outstanding
49,768,669
Dividend Yield
-
PE Ratio
-7.10
Earnings Per Share (EPS)
-1.44
Revenue
-
Net Profit
-71.9M

About Mineralys Therapeutics Inc

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase in... Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.mineralystx.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Mineralys Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MLYS. The last closing price for Mineralys Therapeutics was US$10.36. Over the last year, Mineralys Therapeutics shares have traded in a share price range of US$ 8.58 to US$ 16.905.

Mineralys Therapeutics currently has 49,768,669 shares outstanding. The market capitalization of Mineralys Therapeutics is US$515.60 million. Mineralys Therapeutics has a price to earnings ratio (PE ratio) of -7.10.

Ask ADVFN Intelligence (AI)

MLYS Latest News

More News

Form 8-K - Current report

January 08 2025
Edgar (US Regulatory)

Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension

– Estimated 54 million people suffer from obstructive sleep apnea in the U.S. including 30-50% of adults with hypertension, both conditions associated with excess morbidity and mortality – –...

January 08 2025
GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

November 13 2024
Edgar (US Regulatory)

Form S-8 - Securities to be offered to employees in employee benefit plans

November 12 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

November 12 2024
Edgar (US Regulatory)

Form 8-K - Current report

November 12 2024
Edgar (US Regulatory)

Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

– Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025 – – Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate...

November 11 2024
GlobeNewswire Inc.

Mineralys Therapeutics to Participate in Upcoming Investor Conferences

RADNOR, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension...

November 05 2024
GlobeNewswire Inc.

Form 8-K - Current report

October 30 2024
Edgar (US Regulatory)

Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension

– Topline data now anticipated in mid first half of 2025 – – Management to host virtual KOL event today to discuss the unmet need in hypertension, as well as a review of the ongoing pivotal...

October 30 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.010.097465886939610.2610.799.56523889210.14580235CS
4-2.06-16.707218167112.3313.378.627746110.42397702CS
12-4.72-31.48765843914.9915.048.623062211.9641307CS
26-2.62-20.325833979812.8915.258.5818935712.07707377CS
52-0.61-5.6066176470610.8816.9058.5818534612.67225697CS
156-10.83-51.32701421821.121.985.8518695012.81118868CS
260-10.83-51.32701421821.121.985.8518695012.81118868CS

MLYS - Frequently Asked Questions (FAQ)

What is the current Mineralys Therapeutics share price?
The current share price of Mineralys Therapeutics is US$ 10.27
How many Mineralys Therapeutics shares are in issue?
Mineralys Therapeutics has 49,768,669 shares in issue
What is the market cap of Mineralys Therapeutics?
The market capitalisation of Mineralys Therapeutics is USD 515.6M
What is the 1 year trading range for Mineralys Therapeutics share price?
Mineralys Therapeutics has traded in the range of US$ 8.58 to US$ 16.905 during the past year
What is the PE ratio of Mineralys Therapeutics?
The price to earnings ratio of Mineralys Therapeutics is -7.1
What is the reporting currency for Mineralys Therapeutics?
Mineralys Therapeutics reports financial results in USD
What is the latest annual profit for Mineralys Therapeutics?
The latest annual profit of Mineralys Therapeutics is USD -71.9M
What is the registered address of Mineralys Therapeutics?
The registered address for Mineralys Therapeutics is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Mineralys Therapeutics website address?
The website address for Mineralys Therapeutics is www.mineralystx.com
Which industry sector does Mineralys Therapeutics operate in?
Mineralys Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
FOXXFoxx Development Holdings Inc
US$ 6.355
(119.90%)
33.52M
BHILBenson Hill Inc
US$ 3.925
(118.06%)
13.52M
TECXTectonic Therapeutic Inc
US$ 55.18
(114.54%)
5.46M
AMODAlpha Modus Holdings Inc
US$ 3.2299
(109.73%)
125.47M
DOMHDominari Holdings Inc
US$ 3.61
(59.03%)
4.24M
CLEUChina Liberal Education Holdings Ltd
US$ 0.149
(-98.08%)
311.38M
CRGXCARGO Therapeutics Inc
US$ 3.39
(-74.30%)
21.21M
TDTHTrident Digital Tech Holdings Ltd
US$ 1.0159
(-58.87%)
2.46M
EVTVEnvirotech Vehicles Inc
US$ 0.338202
(-49.30%)
4.78M
IRWDIronwood Pharmaceuticals Inc
US$ 2.29
(-38.44%)
10.53M
NVDANVIDIA Corporation
US$ 124.65
(0.77%)
392.11M
CLEUChina Liberal Education Holdings Ltd
US$ 0.149
(-98.08%)
311.38M
MGOLMGO Global Inc
US$ 0.1199
(17.90%)
166.88M
SPGCSacks Parente Golf Inc
US$ 0.93
(57.63%)
129.08M
RIMEAlgorhythm Holdings Inc
US$ 0.02465
(-5.19%)
126.09M

Discussion

View Full Feed
sentiment_stocks sentiment_stocks 5 minutes ago
I prefer two spaces after a period… not bc I’m a boomer (although I am), but because I think it makes the text easier and more inviting to read. One space runs the individual sentences too close together, IMO. :)
NWBO
kazzy kazzy 7 minutes ago
United States LNG Export Terminals Approved, Not Yet Built

There is only line item (MC1) under MARAD/USCG.

https://www.ferc.gov/media/us-lng-export-terminals-existing-approved-not-yet-built-and-proposed

As of January 28, 2025
Updated to reflect cha
TGLO
green maschine green maschine 13 minutes ago
No, you go figure what the truth is. Just ask ChatGPT or MSFT Copilot, or some other Ai program to get some real answers to your misled beliefs. Dude you are waaay off base with your ideas.
TNXP
Jbone22 Jbone22 16 minutes ago
I used to think it wasn't bad that I had around a .06-.07 average. Now I feel it's gonna take a huge pump to get to .01 
OWCP
236T568 236T568 23 minutes ago
Yet another one 

https://x.com/acnewsitics/status/1884957033197097340?s=19
Menace212 Menace212 25 minutes ago
What makes it even more incredible enticing is if we get even 1 fda approval we will go straight towards 50 cents and above if the cards are played correctly Rspi can become a impactful participant if not a mougel in the pharmaceutical sector considering how we have multiple compounds that have been
RSPI
TradingCharts TradingCharts 38 minutes ago
Amprius SiCore: The Battery That Will Revolutionize EVs and Drones
[yt]yM4QkRee3cY[/yt]
AMPX
gbb777 gbb777 39 minutes ago
https://news.bloomberglaw.com/tech-and-telecom-law/us-armys-development-of-microsoft-goggles-wins-nominees-praise

President Donald Trump’s nominee for Army secretary praised the service for a strategy that may lead to the purchase of thousands of high-tech goggles developed by Microso
VTSI
price_and_volume price_and_volume 45 minutes ago
You wouldnt be underwater if you did.
style="caret-color: rgb(29, 38, 46); color: rgba(29, 38, 46, 1); font-family: DMSans-Regular, sans-serif; font-size: 20.295px" Nobody reads your BS  style="font-size: 1em"You apparently have no idea how to discern truth from fiction, which is why
ENZC
DKLN DKLN 46 minutes ago
Shareholders have never been taken care with zippo substantive accomplishments in 6+ years. Also, potential investors couldn't care less about pushers saying, numerous times, they believe when pushers refuse to buy this near triple zero stock.

MCIC - To Uranus
MCIC
DewDiligence DewDiligence 53 minutes ago
MAZE IPOs 10.1* shares @$16.00:

https://www.globenewswire.com/news-release/2025/01/31/3018524/0/en/Maze-Therapeutics-Announces-Pricing-of-Upsized-Initial-Public-Offering.html Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to dev
LovePennyStock LovePennyStock 53 minutes ago
Yep, my first selling order is $5, and my target price is above $9. Let it rock and roll. It will be our first big winner in 2025 !!!!!!
QMMM
rocketeer357 rocketeer357 54 minutes ago
Yup. Looks like the Dodgers vs cannon fodder for at least the 2025 season. Much longer if injuries don't hit LA too hard.

Small market teams are going to find it harder and harder to open the wallet for FA signings and contract extensions. With no plausible shot at doing any better th
DewDiligence DewDiligence 57 minutes ago
Metsera—(MTSR)—IPOs 17.6M* shares @$18.00—raising ~$300M* in_net proceeds:

https://www.globenewswire.com/news-release/2025/01/30/3018515/0/en/Metsera-Announces-Pricing-of-Initial-Public-Offering.html

*Assuming exercise of underwriter’s option.
Risk vs Reward Risk vs Reward 60 minutes ago
True maybe Mo stopped selling for a few hours lol 
KULR
manibiotech manibiotech 1 hour ago
Hey Ds
You never answered the question in the past as well.
So what is Baker Bros holding of NWBO stock ?
Would ZERO be the right answer ?
NWBO
weedtrader420 weedtrader420 1 hour ago
☝️🤑☝️
BTCUSD
JusDePomme JusDePomme 1 hour ago
#1 on breakout board today!!! Wow tomorrow gonna be fun day
AFFU
vinmantoo vinmantoo 1 hour ago
dewphile, granted we can't really compare the L protein inhibitor from Shionogi and ENTA giving the paucity of data in the Shionogi press release. Just for an exercise let's assume they are measuring the same thing, active virus in a cell culture assay. The difference between viral reduction of 88%
ENTA
littlejohn littlejohn 1 hour ago
Deepseek had slave labor cost or zero in

the development numbers put out

by many media sites...

Budget breakdown for Development,,,

zero labor cost for years...

zero cost for buildings and equipment...

zero cos
Top Penny Top Penny 1 hour ago
My song to all the $$$$$$PSRU$$$$ HATERS!!!!

https://www.youtube.com/watch?v=SdJAhvTSsI4
PSRU
Huggy Bear Huggy Bear 1 hour ago
The HMBL SCAM stock no longer has any IP.

Foote - Lucy.

IP assets - the football.

Shareholders - Charlie Brown.
HMBL

Your Recent History

NASDAQ
MLYS
Mineralys Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads